tablets AM-Aliter are shown in arterial hypertension and/or coronary heart disease (if treatment perindoprily and amlodipiny is necessary).

Structure

Active ingredients: perindoprit, amlodipin;

1 tablet supports a perindopril is grated - to butylamine - 4 mg that is equivalent to 3.338 mg of a perindopril and an amlodipin besilat 13.870 mg that is equivalent - 10 mg of an amlodipin;

Excipients: lactose monohydrate, cellulose microcrystalline krospovidon; Natrii hydrocarbonas; silicon dioxide colloidal stearate of magnesium.

Contraindication

• hypersensitivity to active ingredients (either to the APF any other inhibitors, or to dihydropyridine derivatives) or to excipient;
• Quincke's disease in the anamnesis connected with the previous treatment by APF inhibitors;
• congenital or idiopathic Quincke's disease;
• heavy arterial hypotension;
• shock, including cardiogenic shock;
• obstruction of an exit from a left ventricle (for example, a stenosis of an aorta of heavy degree);
• heart failure after an acute myocardial infarction with an unstable hemodynamics;
• pregnancy or planning of pregnancy;
• simultaneous use with medicaments which contain active ingredient aliskiren, to patients with diabetes or a renal failure (glomerular filtration rate <60 ml/min. / 1.73 sq.m);
• simultaneous use with sakubitrily / valzartany;
• extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces;
• considerable bilateral stenosis of renal arteries or stenosis of an artery of the only kidney.

Route of administration

For oral administration.

on 1 tablet a day once, it is desirable in the morning before food. The tablet is not subject to the section.

Dose should be selected individually for each patient taking into account indications for use, a course of the disease and indicators of arterial blood pressure. The maximum daily dose - 1 tablet of 8 mg / 10 mg a day.

with clearance of creatinine ≥ 60 ml/min. and it is not necessary to appoint to patients with clearance of creatinine <60 ml/min. Individual selection of a dose of each of medicament components separately is recommended to such patients.

At good tolerance of a dose of an amlodipin is identical to patients of young and advanced age. For patients of advanced age the usual mode of dosing is recommended, but increase in a dose needs to be carried out with care.

Pregnant

Use of the medicament AM-Aliter is contraindicated to

Feature of use

AM-Aliter is not recommended to appoint

to children due to the lack of researches with the assistance of this group of patients.

Drivers

Is recommended to be careful, especially in an initiation of treatment.

Overdose

About cases of overdose of the medicament AM-Aliter was not reported.

Side effects

Most frequent side reactions at separate use of a perindopril and amlodipin are: hypostases, drowsiness, dizziness, a headache (especially in an initiation of treatment), a food faddism (dysgeusia), paresthesias, disorders of vision (including doubling), a ring in ears, palpitation, inflows, hypotension (and the related symptoms), short wind, cough, an abdominal pain, nausea, vomiting, dyspepsia, change of a rhythm of defecation, diarrhea, a constipation, an itching, rash, hypostasis of joints (hypostasis of anklebones), spasms soft muscles, increased fatigue, an asthenia.

Simultaneous use is contraindicated to

.

Aliskiren. At patients with diabetes, or patients with impaired renal function the risk of emergence of a hyperpotassemia, deterioration in function of kidneys and cardiovascular incidence and lethality increases.

Extracorporal methods of treatment. Extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces, such as dialysis or haemo filtration with use of certain membranes with high hydraulic permeability (for example, polyacrylonitrile) and aferez lipoproteids of low density using a sulfate dextran, because of the increased risk of development of anaphylactoid reactions of heavy degree. In case of need performing such treatment it is necessary to consider the possibility of use of a dialysis membrane of other type or use of other class of antihypertensive drugs.

Sakubitril / valsartan. Simultaneous use of a perindopril with sakubitrily / valzartany is contraindicated as the simultaneous inhibition of a neprilizin and APF can lead to increase in risk of developing a Quincke's disease. It is necessary to begin use of a sakubitril / valsartan not earlier than in 36 hours after reception of the last dose of a perindopril. Therapy perindoprily should be begun not earlier than in 36 hours after reception of the last dose of a sakubitril / valsartan.

Storage conditions

to Store

at a temperature not above 30 °C in original packing.

to Store

out of children's reach.

Expiration date - 2 years.